Clinical Trial Update: Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder [Phase 3]

View source ↗

Summary

A Phase 3 open-label trial investigating atomoxetine's impact on academic outcomes in children aged 8-11 with ADHD has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED